Treatment of IBD and IBS Using Both Probiotic Bacteria and Fermented Cereal as Treatment

Abstract

The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effecter. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease.

1 . A daily dosage form containing from 18 grams to 90 grams, by dry weight, of a fermented cereal composition comprising at least 1×10 11  colony forming units (CFU) of  Lactobacillus plantarum  299 or  Lactobacillus plantarum  299v per 18 grams, by dry weight, of said fermented cereal;
 wherein said fermented cereal is obtained by fermenting a cereal gruel with a culture of said  L. plantarum  299 or  L. plantarum  299v; and 
 wherein the fermented cereal composition has a pH of less than 5.5. 
 
     
     
         2 . The dosage form according to  claim 1 , wherein said fermented cereal is obtained by fermenting a cereal gruel with a culture of  L. plantarum  299 or  L. plantarum  299v for at least 12 hours. 
     
     
         3 . The dosage form according to  claim 1 , wherein said fermented cereal is obtained by fermenting a cereal gruel with a culture of  L. plantarum  299 or  L. plantarum  299v for at least 24 hours. 
     
     
         4 . The dosage form according to  claim 1  containing at least 0.05 gram, by dry weight, of said fermented cereal per mL of said fermented cereal composition. 
     
     
         5 . The dosage form according to  claim 1  containing at least 0.10 gram, by dry weight, of said fermented cereal per mL of said fermented cereal composition. 
     
     
         6 . The dosage form according to  claim 1  containing at least 0.18 gram, by dry weight, of said fermented cereal per mL of said fermented cereal composition. 
     
     
         7 . The dosage form according to  claim 1 , wherein the fermented cereal comprises at least 1×10 8  cfu/mL of  L. plantarum  299 or  L. plantarum  299v. 
     
     
         8 . The dosage form according to  claim 1 , wherein the fermented cereal comprises at least 1×10 9  cfu/mL of  L. plantarum  299 or  L. plantarum  299v. 
     
     
         9 . The dosage form according to  claim 1 , wherein the cereal gruel that is fermented is selected from the group consisting of barley, corn, millet, oats, oatmeal,  quinoa , rice, rye, sorghum, triticale, wheat, and cassava. 
     
     
         10 . The dosage form according to  claim 1 , wherein the cereal gruel that is fermented is oat or oatmeal. 
     
     
         11 . A method for remission treatment of a gastrointestinal disease in a human being caused by pro-inflammatory microorganisms, said method comprising the step of administering to said human being, on a daily basis, a therapeutically effective amount of the dosage form according to  claim 1 . 
     
     
         12 . The method of  claim 11 , wherein the gastrointestinal disease is a chronic inflammatory disease. 
     
     
         13 . The method of  claim 11 , wherein the gastrointestinal disease is inflammatory bowel disease (IBD). 
     
     
         14 . The method of  claim 11 , wherein the gastrointestinal disease is irritable bowel syndrome (IBS). 
     
     
         15 . The method of  claim 11  further comprising administering to said human being, on a daily basis, a therapeutically effective amount of an active agent selected from the group consisting of 5-aminosalicylic acid (5-ASA), a corticosteroid, and an immune-modulatory medicament. 
     
     
         16 . The method of  claim 15 , wherein the active agent is 5-aminosalicylic acid (5-ASA). 
     
     
         17 . A method for maintenance treatment of a gastrointestinal disease in a human being caused by pro-inflammatory microorganisms, said method comprising the step of administering to said human being, on a daily basis for a period of from 1 to 25 weeks, a therapeutically effective amount of the dosage form according to  claim 1 . 
     
     
         18 . The method of  claim 17 , wherein the gastrointestinal disease is a chronic inflammatory disease. 
     
     
         19 . The method of  claim 17 , wherein the gastrointestinal disease is inflammatory bowel disease (IBD). 
     
     
         20 . The method of  claim 17 , wherein the gastrointestinal disease is irritable bowel syndrome (IBS). 
     
     
         21 . The method of  claim 17  further comprising administering to said human being, on a daily basis, a therapeutically effective amount of an active agent selected from the group consisting of 5-aminosalicylic acid (5-ASA), a corticosteroid, and an immune-modulatory medicament. 
     
     
         22 . The method of  claim 21 , wherein the active agent is 5-aminosalicylic acid (5-ASA).